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Abstract
Background: The aim is to describe the association of functional capacity and
cognitive functioning with 1-year mortality in older patients with cancer in the head
and neck region.
Methods: We performed a cohort study in which all patients aged 70 years and older
received a geriatric screening before treatment. Main outcome was 1-year mortality.
Results: A total of 102 patients were included. Median age was 78.7 years (inter-
quartile range [IQR], 72.3-84.5), 25% were cognitive impaired, 40% were malnour-
ished, and 28.4% used a walking device. Overall, 1-year mortality was 42.3%.
Male sex (hazard ratio [HR], 4.30; 95% confidence interval [CI], 1.35-13.67), mal-
nutrition (HR, 2.55; 95% CI, 1.19-5.16), and using a walking device (HR, 2.80;
95% CI 1.13-6.93) were associated with higher mortality risk, independent of stage
and comorbidities.
Conclusion: In older patients with head and neck cancer, the mortality rates are
high. Nutritional status and mobility are determinants of 1-year mortality, indepen-
dent of tumor stage, age, and comorbidity.
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1 | INTRODUCTION
Patients diagnosed with head and neck cancer (HNC) are, in
case of curative intention, facing major treatment options,
such as extensive operation and/or (chemo)radiation therapy.
Older patients in general are at higher risk for adverse health
outcomes (such as delirium, complications, and longer dura-
tion of stay) after treatment, but the risk for patients with
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HNC is even higher because of a high prevalence of previous
excessive alcohol drinking and smoking,1–3 which makes this
group more susceptible for cognitive3,4 and functional5
decline. It could be important to make a careful selection of
the patients who are suitable for the intensive treatment. In the
United States, it is expected that between 2010 and 2030, the
incidence of oral cavity and pharyngeal cancer in patients aged
65 years and older will increase by 61%.6 Besides, the 5-year
survival is poor with an estimated survival of 50% with a large
variation between the different tumor localizations.7,8 How-
ever, limited evidence is available on the association of a geri-
atric assessment with adverse health outcomes and the role of
assisting clinical decision making in older patients with HNC.
Across a variety of (surgical) oncologic population and can-
cer types, components of the geriatric assessment, such as cog-
nition, functional status, and social status, are predictive for
adverse health outcomes such as postoperative complications,
institutionalization after discharge, and mortality.9,10 Several
guidelines recommend for a form of geriatric assessments as
part of routine preoperative care.11,12 A recent systematic review
in older patients with HNC showed that geriatric conditions
were prevalent and in 64% of the included studies there was a
statistically significant association of geriatric impairments with
a higher risk of adverse outcome.13 However, cognitive function
and objectively measured physical capacity were not assessed.
The aim of this study is to describe the association in
older patients with cancer in the head and neck region of
geriatric measurements, including functional capacity and
cognitive functioning, with 1-year mortality.
2 | METHODS
2.1 | Study design and setting
We performed a retrospective cohort study (from October 2014
until January 2017) in older patients seen with cancer in the
head and neck region in the Leiden University Medical Centre
(LUMC). From October 2014, a routine clinical care pathway
was implemented in which all older patients with HNC were
referred to the Department of Gerontology and Geriatrics for a
geriatric screening before treatment. The result of this geriatric
screening was discussed in the multidisciplinary team. Patients
were referred when aged 70 years and older, or younger but
with multiple comorbidities, diagnosed with stage III-IV HNC,
or diagnosed with a lower stage HNC but needing invasive
treatment, for geriatric screening before their invasive treat-
ment. In this study, HNC was considered as cancer in the head
and neck region needing invasive treatment by the head and
neck surgeon. This includes cancer in the sinonasal or oral
regions, nasopharynx, oropharynx, hypopharynx, supraglottic,
the larynx, the salivary glands, or the proximal esophagus.
However, also patients with large or regionally metastasized
dermal cancer, lymphoma, an unknown primary, or a recurrent
tumor were referred for geriatric assessment. Patients with thy-
roid cancer are not included in this study, because in the Neth-
erlands thyroid cancer is not treated by a head and neck
surgeon. For the retrospective collection and analysis of the
data from these patients, the Medical Ethical Committee of the
LUMC issued a “certificate of no objection.”
2.2 | Determinants
Collected demographics were age, sex, marital status, and level
of education. High education level was defined as university or
higher vocational training and low education is defined as ele-
mentary school, community college, and secondary education.
The Adult Comorbidity Evaluation-27 score (ACE-27) was
calculated.14 The ACE-27 has specifically been developed for
patients with cancer in general. This index contains 27 different
comorbidities from various organ systems. Grade 0 corresponds
to no comorbidity, grade 1 to mild comorbidity, grade 2 to
moderate comorbidity, and grade 3 to severe comorbidity.15,16
Disease severity indicators consisted of tumor site, tumor stage,
and whether the tumor was a new primary tumor. Tumor stage
was directly extracted from the medical record.17 Geriatric
measurements were the Katz Index of Independence in Activi-
ties of Daily Living (Katz ADL),18 the Lawton Instrumental
Activities of Daily Living (IADL),19 the 6-Item Cognitive
Impairment Test (6CIT),20 the Mini Nutritional Assessment
(MNA),21 and the Identification of Seniors At Risk—
Hospitalized Patients questionnaire (ISAR-HP).22 The Katz
ADL score ranges from 0 to 6 and the Lawton IADL score
ranges from 0 to 24, a higher score corresponds to more func-
tional dependency. The 6CIT is a short cognition test20 and has
a maximum score of 28 points, in this routine clinical care
pathway, a score ≥8 is considered as abnormal, suggesting
cognitive impairment. Nutritional status was assessed with the
MNA questionnaire, a screening tool consisting of 6 questions
to estimate the risk of malnutrition,21 a cutoff point of ≤11 was
used to define (the risk for) malnutrition. The ISAR-HP ranges
from 0 to 5 and is a screening tool to assess the risk for devel-
opment of functional decline. A cutoff point of ≥2 points was
used to define this risk.22 Furthermore, the use of a walking
device was extracted from the medical record.
2.3 | Outcome
The main outcome of this study was mortality at 12 months
of follow-up after start of treatment. Mortality data were
extracted from the municipal records.
2.4 | Statistical methods
Baseline characteristics are presented as mean with SD in
case of normal distribution, median with interquartile range
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(IQR) in case of skewed distribution, or as numbers with
percentages. Different groups were compared using the t test
for continuous normally distributed data, chi-square test for
categorical data, and the Mann-Whitney U test for skewed
data. To investigate the association between baseline charac-
teristics and mortality, a Cox regression model was used. In
the multivariable model (Table 2), treatment intention was
not used as a determinant, to avoid overcorrection, because
treatment intention is based on all the other determinants. In
the multivariable analysis reported in Table 3, we stratified
the analysis for curative intention. Hazard ratios with 95%
confidence intervals (CI) were calculated, and a P-value of
<0.05 was considered significant. All analyses were per-
formed using SPSS (IBM version 23; IBM Corp., Armonk,
New York).
3 | RESULTS
A total of 102 older patients with HNC were included in the
present study. Table 1 shows the baseline characteristics of
this population. The median age was 78.7 years (IQR,
72.3-84.5) and 71 patients (69.6%) were men. Mild or mod-
erate comorbidity was observed in 71 patients (69.6%) and
25 patients (24.5%) had severe comorbidity. A minority of
the patients were diagnosed with skin cancer in the head and
neck region (24.5%). Most patients (n = 72) had a newly
diagnosed head and neck tumor (70.6%), and 62 patients
(65.6%) had stage III-IV cancer. More than 25% of the
patients had cognitive impairment, almost 40% had (risk for)
malnutrition, more than 40% had an abnormal ISAR-HP,
and 28.4% of the included patients used a walking device.
Figure 1 shows the cumulative survival curve of all
included patients. Within 1 year, 42.3% of the patients were
deceased. Table 2 shows the risk of 1-year mortality for
baseline determinants for all included patients. In the uni-
variable analysis, several determinants were associated with
an increased mortality; a low BMI with a hazard ratio (HR,
0.89; 95% CI, 0.83-0.95) compared to a higher BMI, stage
III-IV (HR, 4.12; 95% CI, 1.61-10.60) compared to stage
I-II, and treatment with palliative intention (HR, 5.16; 95%
CI, 2.74-9.72) compared to curative intention. Also, (risk
for) malnutrition was associated with an increased mortality
(HR, 3.40; 95% CI, 1.83-6.33) compared to no (risk for)
malnutrition and also dependency in IADL functioning (HR,
1.07; 95% CI, 1.02-1.12) compared with no dependency.
Independent factors for a higher risk for 1-year mortality
were male sex (HR, 4.30; 95% CI, 1.35-13.67), an abnormal
MNA score (HR, 2.55; 95% CI, 1.19-5.16), and the use of a
walking device (HR, 2.80; 95% CI, 1.13-6.93).
Figure 2 shows the sensitivity analysis in which we strati-
fied the cumulative survival to treatment intention. After
12 months of follow-up, 74.3% (n = 26) of the patients
TABLE 1 Baseline characteristics of the total study population
Characteristics
No. of
participants = 102
Patient characteristics
Age (years), median (IQR) 78.7 (72.3-84.5)
Male sex, n (%) 71 (69.6)
Married, n (%) 55 (53.9)
Educational level, n (%)
Low 67 (75.3)
High 22 (24.7)
ACE-27 score, n (%)
No comorbidity 6 (5.9)
Mild comorbidity 37 (36.3)
Moderate comorbidity 34 (33.3)
Severe comorbidity 25 (24.5)
Number of drugs, median (IQR) 6 (2.3-8)
BMI, median (IQR) 24.6 (21.6-26.9)
Smoking history, n (%) 82 (83.7)
Alcohol units/week, median (IQR) 5.0 (0-14)
Disease specific
Tumor site, n (%)
Oral cavity 24 (23.5)
Pharynx 24 (23.5)
Larynx 9 (8.8)
Salivary gland 8 (7.8)
Skin of head and neck region 24 (24.5)
Othera 13 (12.7)
New primary tumor 72 (70.6)
Stage grouping, n (%)
I-II 33 (34.4)
III-IV 62 (65.6)
Treatment goal, n (%)
Curative 67 (65.7)
Palliative 35 (34.3)
Geriatric domains
Cognitive impairment, n (%) 25 (25.3)
Functional dependent, n (%) 14 (13.7)
Dependent in IADL function, n (%) 10 (9.9)
Risk of malnutrition or
malnourished, n (%)
40 (39.2)
Risk for functional decline
after hospitalization, n (%)
24 (41.4)
Use of a walking device, n (%) 29 (28.4)
Abbreviations: ACE-27, Adult Comorbidity Evaluation Score; IADL = Indepen-
dent Activities in Daily Living; IQR, interquartile range; MNA, Mini Nutritional
Assessment; n, number.
Data incomplete for educational level (n = 89), number of drugs (n = 100),
BMI (n = 101), smoking history (n = 98), alcohol consumption (n = 97), stage
of disease (n = 96), 6-CIT score (n = 99), IADL score (n = 101).
aIn the other group were included: unknown primary tumor, sinonasal tumor, proxi-
mal esophagus tumors, lymphoma of head and neck and vestibular schwannoma.
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treated with palliative intention were deceased in contrast to
25.4% (n = 17) of the patients treated with curative inten-
tion. The median survival for the patients treated with pallia-
tive intention was 6.3 months. Table 3 shows the risk of
1-year mortality for baseline determinants for the patients
treated with curative intention. Independent factors for a
higher risk for 1-year mortality were male sex (HR, 27.64;
95% CI, 1.56-490.1), (risk for) malnutrition (HR, 6.81; 95%
CI, 1.84-25.22) compared to no (risk for) malnutrition, and
the use of a walking device (HR, 6.93; 95% CI, 1.58-30.46)
compared with no use of a walking device.
4 | DISCUSSION
The main findings of this study are that the mortality rate is
high, even in the patients treated with curative intent and that
(the risk for) malnutrition and mobility were determinants
associated with 1-year mortality, independent of tumor
stage, age, and comorbidity in older patients with cancer in
the head and neck region.
In our study, several geriatric impairments were associ-
ated with 1-year mortality, but after correcting for sex, age,
FIGURE 1 Cumulative survival curve of the total study
population [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 2 The association between baseline characteristics and mortality after 1 year of follow-up of all included patients
Univariable analysis Multivariable analysis
Variable HR 95% CI P-value HR 95% CI P-value
Age 0.99 0.95-1.03 0.50 1.00 0.96-1.05 0.91
Male sex 1.58 0.78-3.20 0.21 4.30 1.35-13.67 0.01
Marital status
Married Ref … …
Single 1.00 0.58-1.82 0.99 … … …
ACE-27 score
0-1 Ref … … Ref … …
2-3 1.77 0.91-3.44 0.09 1.42 0.65-3.08 0.38
Number of drugs 1.00 0.92-1.07 0.79 0.97 0.89-1.07 0.59
BMI 0.89 0.83-0.95 0.001 … … …
Stage of disease
0-II Ref … … Ref … …
III-IV 4.12 1.61-10.60 0.003 2.03 0.79-5.27 0.14
Goal of treatment
Curative Ref … …
Palliative 5.16 2.74-9.72 <0.001 … … …
Cognitive impairment 1.73 0.91-3.29 0.09 1.76 0.61-5.07 0.29
(Risk for) malnutrition 3.40 1.83-6.33 <0.001 2.55 1.23-5.26 0.01
Functional dependent 1.07 0.93-1.18 0.44 … … …
Dependent in IADL function 1.07 1.02-1.12 0.01 1.07 0.97-1.17 0.20
Use of a walking device 1.77 0.95-3.29 0.07 2.80 1.13-6.93 0.03
Abbreviations: 6-CIT, 6-Item Cognitive Impairment Test; 95% CI, 95% confidence interval; ACE-27, Adult Comorbidity Evaluation Score; ADL, Activities in Daily
Living; IADL, Independent Activities in Daily Living; HR, hazard ratio; MNA, Mini Nutritional Assessment.
Multivariate analysis was done with complete data for 85 patients.
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and disease-specific determinants, only the use of a walking
device was independently associated with 1-year mortality.
Our recently published systematic review reports that in 64%
of the reported associations, a decline in functional or cogni-
tive impairment, mood, or social environment was associ-
ated with adverse outcomes.13 Very little is known about the
use and the predictive value of a geriatric assessment in
HNC, because most of the studies included low patient num-
bers and therefore have a lack of power. In other fields of
medicine, a geriatric assessment is well established to guide
decision making or to identify unknown geriatric impairments
(such as cognitive impairment and functional dependency),
which can be taken into account before or during treat-
ment.23,24 To our knowledge, it is not previously reported that
the use of a walking device is associated with 1-year mortality.
In this cohort, the 1-year mortality rates are high: 42.3%
overall in the included patients, but also 25% of the patients
treated with curative intent are deceased within 1 year. In
general, the 5-year survival in patients with HNC is around
50% depending on tumor stage, tumor type, and treatment
intention.7,8 Treatment with curative intention can contain
chemoradiation or an operation (depending on the type of
HNC) and followed by (chemo)radiation therapy when indi-
cated. In patients aged 70 years and older, adding chemo-
therapy to radiotherapy does not contribute to higher
survival rates.25,26 Life expectancy is obviously lower when
getting older and therefore could be taken into account. The
knowledge of the survival rates, the extensiveness of the
treatment, and the predictors reported in this study, and in
order to personalize the treatment plan for this vulnerable
population, more research should be done.
We found a relatively high prevalence of geriatric impair-
ments. For example, a quarter of the included patients were
cognitively impaired. Compared to the limited literature
available, the proportion of patients who are cognitively
impaired reported in our study could potentially even be
higher. Williams et al. describe 83 adults with HNC before
treatment and report that more than 50% were cognitively
impaired.27 The study of Bond et al. describes 70 patients
with HNC and reports around 47% of cognitively impaired
patients.28 So, probably the cognition test used in our study
was not comprehensive enough to recognize subtle cognitive
impairment. The clinical implications of cognitive impair-
ment before treatment are not well described in literature,
but most likely negatively affect patients with HNC like in
other fields of oncologic medicine.29 In these fields, it is
known that being cognitively impaired before treatment
gives a higher risk for adverse health outcomes such as tox-
icity, not able to finish treatment, side effects, and mortal-
ity.28,30 Besides, it is probably more difficult for patients
with cognitive dysfunction to weigh the risk and benefits for
cancer treatment, which impedes good shared decision mak-
ing, to comply with the treatment plan and to adequately ask
for medical attention if necessary. Therefore, it could be
informative for the patient as well as the treating specialist to
have insight in the cognitive status and to take this informa-
tion into account.
There are some limitations to our study. First, the included
study population was relatively small. Second, the outcome
of this study was mortality, whereas remaining functional
and cognitive independent and quality of life would be also
FIGURE 2 Cumulative survival curve stratified into treatment
intention
TABLE 3 Independent determinants for 1-year survival in
curative treated patients
Multivariable analysis
Variable HR 95% CI P-value
Age 1.04 0.95-1.14 0.35
Male sex 27.64 1.56-490.1 0.02
ACE-27 score
0-1 Ref … …
2-3 2.41 0.65-8.95 0.19
Number of drugs 1.00 0.86-1.16 0.99
Stage of disease
0-II Ref … …
III-IV 0.77 0.19-3.02 0.70
Cognitive impairment 2.74 0.51-14.85 0.24
(Risk for) malnutrition 6.81 1.84-25.22 0.004
Dependent in IADL functioning 1.05 0.88-1.24 0.59
Use of a walking device 6.93 1.58-30.46 0.01
Abbreviations: 6-CIT, 6-Item Cognitive Impairment Test; 95% CI, 95% confi-
dence interval; ACE-27, Adult Comorbidity Evaluation Score; ADL, Activities
in Daily Living; IADL, Independent Activities in Daily Living; HR, hazard ratio;
MNA, Mini Nutritional Assessment.
Multivariate analysis was done with complete data for 60 patients. The bold
values are statistically significant.
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interesting outcomes to assess. Finally, the tumor types in the
present study were heterogeneous. Strengths of this study
include the relatively unselected patient cohort which has a
result that the included patients in this study were a reflection
of the older patients with HNC seen in clinical practice. All
included participants underwent a comprehensive geriatric
assessment. And this study complements the, until now lim-
ited, available literature.
5 | CONCLUSIONS
In older patients with HNC, the mortality rates are high.
Nutritional status and mobility are determinants of 1-year
mortality, independent of tumor stage, age, and comorbidity.
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